Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function.Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years.With the failure of these inhibitors in clinical trials,more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs , a brief description of available threedimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
Keywords: Matrix metalloproteinases, MMP inhibitors, Zinc-binding groups, cancer, computer-aided drug design, angiogenesis, metastasis, proteases
Current Medicinal Chemistry
Title: Progress in the Development of Matrix Metalloproteinase Inhibitors
Volume: 15 Issue: 14
Author(s): GuoGang Tu, WenFang Xu, HuiMing Huang and ShaoHua Li
Affiliation:
Keywords: Matrix metalloproteinases, MMP inhibitors, Zinc-binding groups, cancer, computer-aided drug design, angiogenesis, metastasis, proteases
Abstract: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function.Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years.With the failure of these inhibitors in clinical trials,more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs , a brief description of available threedimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
Export Options
About this article
Cite this article as:
Tu GuoGang, Xu WenFang, Huang HuiMing and Li ShaoHua, Progress in the Development of Matrix Metalloproteinase Inhibitors, Current Medicinal Chemistry 2008; 15 (14) . https://dx.doi.org/10.2174/092986708784567680
DOI https://dx.doi.org/10.2174/092986708784567680 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Joint Diseases and Matrix Metalloproteinases: A Role for MMP-13
Current Pharmaceutical Biotechnology Vaccination and Rheumatic Diseases: Is There Still a Dilemma?
Current Rheumatology Reviews The Effects of Non-Steroidal Anti-Inflammatory Drugs (Selective and Non-Selective) on the Treatment of Periodontal Diseases
Current Pharmaceutical Design Statistical Analysis, Optimization, and Prioritization of Virtual Screening Parameters for Zinc Enzymes Including the Anthrax Toxin Lethal Factor
Current Topics in Medicinal Chemistry IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Lipoxygenases (LOs): An Heterogenous Family of Lipid Peroxidizing Enzymes Implicated in Cell Differentiation, Inflammation, Asthma, Carcinogenesis, Atherogenesis-An Interesting Target for the Development of Promising Drugs
Current Enzyme Inhibition Inflammatory Diseases - New Compounds and Treatments
Current Organic Chemistry Identification of the Active Constituents and Significant Pathways of Guizhi-Shaoyao-Zhimu Decoction for the Treatment of Diabetes Mellitus Based on Molecular Docking and Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) COVID-19: Role of Robotics, Artificial Intelligence and Machine Learning During the Pandemic
Current Medical Imaging Synthesis of Thiazolone Derivatives as Novel Soybean 15-LOX Inhibitors
Letters in Organic Chemistry Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design The Immune Response in SAPHO Syndrome: Deficiency, Hyper- Responsiveness, or Both?
Current Rheumatology Reviews Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) Chemokines and Chemokine Receptors as Targets in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Stress as a Pathophysiological Factor in Functional Somatic Syndromes
Current Psychiatry Reviews